AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
06-10-2026 04:45 via pharmacypracticenews.com

AAM Report: Generics and Biosimilars Saved $496 Billion in 2025

Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzGeneric and biosimilar drugs jointly created $496 billion in savings in 2025 for the U.S. healthcare system and for patients, according to a new report released by the Association for Accessible Medicines and the Biosimilars Council. Savings over the last decade were $3.5 trillion.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure im
Read more »

Pharmacy news



Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
Registry Data Support Treating Mild Tardive Dyskinesia
Registry Data Support Treating Mild Tardive Dyskinesia
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
FDA Approves Degevma, Biosimilar to Xgeva
FDA Approves Degevma, Biosimilar to Xgeva
Financial Success Hinges on Proactive Enterprise Planning
Financial Success Hinges on Proactive Enterprise Planning
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Closing the Rx Gap Between Oncology Guidelines and Practice
Closing the Rx Gap Between Oncology Guidelines and Practice
The Ongoing Struggle of Sickle Cell Disease
The Ongoing Struggle of Sickle Cell Disease
AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models
AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models
Desktop versie